Purpose: Tissue inhibitor of metalloproteinase (TIMP) is known to play a role in age-related macular degeneration (AMD). We wished to investigate alterations in different late stages of AMD: neovascular AMD and geographic atrophy (GA). Methods: This was a prospective case-control study. A total of 125 participants were included consecutively during a period of 18 months. We included 46 patients with neovascular AMD, 46 patients with GA without any sign of choroidal neovascularization in either eye, and 33 healthy aged controls. Patients with immune-affecting disorders were not included. Commercial immunoassay kits were used to quantify levels of TIMP-1, TIMP-3, MMP-2 and MMP-9 in blood plasma. Results: We found that patients with neovascular AMD had lower plasma concentration of TIMP-3 (p = 0.028) than healthy controls. Patients with GA had higher plasma levels of TIMP-1 (p < 0.001) and MMP-9 (p = 0.022) compared to healthy controls. Also, we found that TIMP-1 levels in patients with GA increased with age (Spearman's rho = 0.04, p = 0.006). Conclusion: Matrix metalloproteinases (MMPs) and TIMPs, which are known to be involved in age-related changes in Bruch's membrane, are significantly altered systemically, suggesting the presence of an imbalance in the homeostasis of the extracellular matrix. These imbalances may explain differences in the clinical manifestation of late AMD.
Introduction
Age-related macular degeneration (AMD) is a progressive neurodegenerative disease and a prevalent cause of central blindness among elderly in the Western world (Owen et al. 2012) . The primary hallmark in AMD is basal deposits, which form between Bruch's membrane (BrM) and the retinal pigment epithelium (RPE) (Lim et al. 2012 ). So far, it remains unknown why some patients with AMD who progress to late stage of the disease develop choroidal neovascularization (CNV), whereas others develop geographic atrophy (GA). The two late stages are morphologically very distinct, although their early stages are indistinguishable.
Bruch's membrane (BrM) is an extracellular matrix (ECM) that under healthy conditions facilitates a bidirectional flow of nutrients and waste products between the metabolically active RPE and the choroidal bloodstream. Bruch's membrane (BrM) also acts as a supportive barrier that restricts cellular migration to the retinal layers (Booij et al. 2010) . As in other ECMs, the structural and functional properties of BrM are maintained through closely regulated processes of synthesis and degradation, which orchestrates a continuous remodelling of the membrane (Kamei & Hollyfield 1999) . The degradation of BrM is mediated by MMP, which are proteolytic enzymes. MMPs are released as inactive proenzymes, which when activated are capable of digesting all components of the ECM (Woessner 1991) . Specifically, MMP-2 and MMP-9 are present in the BrM and the presence of their inactive pro-MMP form increases with age (Guo et al. 1999) . MMP-2 and MMP-9 are both known to correlate systemically with inflammatory markers, such as C-reactive protein, interleukin-6 and markers of oxidative stress (Ferroni et al. 2003; Kameda et al. 2003) . Their activity is balanced by the tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-3, which are broad inhibitors of MMPs and also present in the BrM (Woessner 2001) . Active MMPs regulate remodelling of the ECM through their degradative capacity, and TIMPs have inhibitory effect on MMP activity. These processes are thought to maintain the integrity of the BrM (Guo et al. 1999) .
Besides the regulatory functions towards MMPs, TIMP-1 and TIMP-3 have other regulatory properties. Tissue inhibitor of metalloproteinase (TIMP)-3 has distinct anti-angiogenic properties via competitive inhibition of binding between vascular endothelial growth factor (VEGF) and VEGF receptor-2 (Qi et al. 2003) . Although early studies did not find any association between TIMP-3 and AMD (Felbor et al. 1997; Paz et al. 1997) , large genomewide association studies suggest that TIMP-3 is a putative candidate for AMD susceptibility (Chen et al. 2010) . Tissue inhibitor of metalloproteinase (TIMP)-1 is expressed in endothelial cells where it possesses anti-angiogenic properties and inhibits microvascular endothelial cell migration (Akahane et al. 2004) . Tissue inhibitor of metalloproteinase (TIMP)-1 has also been described to inhibit apoptosis and proliferation of different cell lines (Bloomston et al. 2002; Akahane et al. 2004) .
Ageing is the most important risk factor for development of AMD and for progression of AMD to its late clinical phenotypes with CNV or GA. The ageing BrM shows an increased collagen cross-linking, an overall increase in thickness and a reduced filtration capacity, all leading to a diminished metabolic support of the overlying RPE cells (Ramratten et al. 1994) . Ageing of the BrM is thought to play an important role, as the agerelated changes in BrM are exacerbated in AMD (Spraul et al. 1999) . In addition, the effect of MMP-2 and MMP-9 is shown to directly promote choroidal neovascularization (Lambert et al. 2003) .
In this study, we measured blood plasma levels of soluble MMP-2 and MMP-9 as well as TIMP-1 and TIMP-3 to study whether an imbalance is present in patients with late AMD. Compared to existing studies on TIMPs and MMPs, our study is distinguished by providing data on systemic levels on aged individuals who differ clinically by having either CNV only or GA only.
Materials and Methods

Design
This was a prospective case-control study where we compared blood plasma levels of MMPs and TIMPs in patients with neovascular AMD and patients with GA to that of healthy controls. The study was approved by the Regional Committee of Ethics in Research of the Region of Zealand (SJ-385). Oral and written informed consent was obtained from all participants prior to inclusion after explanation of the nature and possible consequences of the study. This study adhered to the tenets of the Declaration of Helsinki.
Study participants and inclusion
We recruited 125 patients from our retinal outpatient programme during a period of 18 months. Patient spouses accompanying them in the clinic were recruited as healthy controls. We employed this recruitment strategy to better match the control group to the patients' environmental exposures. All participants were age 60 or above. Individuals were not included if they had any immunological disorders, infectious disease and cancer or if they received any immune-modulating medication. We also did not include patients if they had received anti-VEGF treatment within the last 6 or 8 weeks for ranibizumab and aflibercept, respectively. We measured plasma C-reactive protein (CRP) and post hoc excluded any participant with plasma CRP above 15 mg/L due to suspected ongoing infection or inflammation (Rifai & Ridker 2001) .
All included participants were interviewed regarding health, use of medication, tobacco and alcohol. Smoking habits were categorized as current smokers, former smokers (no tobacco consumption ≥ 1 year) or never smokers (lifetime consumption of < 100 cigarettes) (Freedman et al. 2008) . Alcohol consumption was registered as self-reported amount of units (12 g ethanol) per week. Height and weight were used to calculate body mass index. Physical activity was quantified using a single question, which has been validated in patients with AMD (Subhi et al. 2014; Subhi & Sørensen 2016) .
Retinal diagnosis
All participants were subjected to thorough ophthalmological examination including best corrected visual acuity, slit-lamp examination, indirect dilated fundoscopy, spectral domain optical coherence tomography (OCT) and fundus autofluorescence (Heidelberg Engineering, Heidelberg, Germany). Fluorescein and indocyanine green angiography were performed in cases of suspected neovascularization.
Participants in the following categories were included:
• Neovascular AMD characterized by drusen maculopathy and exudative changes, including nondrusenoid pigment epithelium detachments, serous or haemorrhagic retinal detachments, CNV with subretinal haemorrhages or fibrosis, corresponding to Clinical Age-Related Maculopathy Staging (CARMS) system grade 5 (Seddon et al. 2006 ).
• Geographic atrophy (GA) characterized by drusen maculopathy and one or more well-defined atrophic area in the macula region of marked decreased retinal pigment visible by fundoscopy and OCT , corresponding to CARMS grade 4. The included patients with GA had no neovascularizations in either eye and no history of neovascular AMD. Patients with subretinal fibrosis or any other sign of former neovascularization were not included in this study group.
• Healthy controls had none or less than 10 small drusen (<63 lm) and where without any pigment abnormalities, equivalent to CARMS grade 1.
Blood sampling and protein quantification
Participants had blood sampled from the antecubital vein in tubes coated with lithium heparin. One tube was used for determining CRP. Another tube was used for plasma isolation and measurement of soluble MMPs and TIMPs. Here, the tube was centrifuged at 1500 g for 15 min to eliminate cells.
Plasma was immediately collected and aliquoted prior to freezing at À80°C.
Plasma TIMP-1, MMP-2 and MMP-9 levels were quantified using commercially available multiplex immunoassays (Meso Scale Discovery, Gaithersburg, Maryland, USA). All analyses were made according to the manufacturer's instructions. Samples were diluted 50-fold in TIMP-1 assay and 10-fold in the MMP-2 and MMP-9 assay. Reading was performed immediately after plate preparation on QuickPlex SQ120 (Meso Scale Discovery, Gaithersburg, Maryland USA), and concentrations were presented in pg/ml using the applied measurements from the 8-point standard curve in each plate.
Plasma TIMP-3 levels were quantified using TIMP-3 Human ELISA Kit (Cat. Nr: Ab119608; Abcam, Cambridge, MA, USA). All analyses were made according to the manufacturer's instructions. Microtiter plates provided in the kit were precoated with TIMP-3 specific antibody. Prespecified dilutions of the standard and plasma samples were added to the plate wells. After incubation, plate contents were discarded and biotin-conjugated specific antibody was added to each well. After further incubation, wells were washed and incubated with enzyme substrate. The reactions were stopped after 20 min, and the colour intensity in each well was measured at 450 nm in a microplate reader (BEP 2000 Advance System; Siemens Healthineers, Erlangen, Germany).
All samples were run in duplicate, and averages of the duplicates were used for analysis. Tests were repeated if the coefficient of variance exceeded 20%. No cases were below detection range for TIMP-1, MMP-2 and MMP-9. For TIMP-3, 25% of the tests were below detection range. Tests were carried out randomly across plates, blinded from diagnosis and any other clinical or demographic factors.
Data analysis and statistics
Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS), version 24 (IBM Corporation, Armonk, NY, USA). Normally distributed data are presented using mean and standard deviation (SD), and comparisons are made using parametrical tests. Not normally distributed data are presented using median and interquartile range (IQR), and comparisons are made using nonparametrical tests. Categorical data are presented in percentage and tested using v 2 test, with the exception of tests with small categories (<5 cases) in which case Fisher's exact test is used. Due to difference of age in the study groups, we use Spearman's rank correlation to assess the possible correlation between age and plasma levels of each TIMP and MMP.
Results
A total of 125 participants were recruited, which consisted of 46 patients with neovascular AMD, 46 patients with GA and 33 healthy age-matched adults. Groups did differ in age, as the group of patients with GA was significantly older than the other groups. To explore the potential effect on our plasma measurements, we calculated the correlation coefficient of age and the concentration of TIMP-1, TIMP-3, MMP-2 and MMP-9. We found no significant correlation in the healthy control group or in the patients with neovascular AMD. In patients with GA, we found a correlation between age and TIMP-1 (q = +0.4, p = 0.006) (Fig. 1) . Besides age, participants did not differ significantly in demographics or lifestyle factors (Table 1) .
We explored the overall plasma concentration of TIMPs and MMPs in study groups and compared these across groups (Fig. 2) . Patients with neovascular AMD had significantly lower levels of TIMP-3 than healthy controls, median 767 versus 1034 pg/ml (p = 0.028, Mann-Whitney U-test). Similarly, TIMP-3 levels in patients with neovascular AMD were also lower than in patients with GA (median 1023 pg/ml), but this difference did not reach statistical significance (p = 0.150, Mann-Whitney U-test).
The ratio between TIMP-3/MMP-2 was significantly decreased in patients with neovascular AMD when compared to healthy controls, median 8.0 versus 11.9 (p = 0.019, Mann-Whitney U-test), suggesting a more MMP-2-dominated profile.
Patients with GA displayed a higher level of TIMP-1, median 335 versus 243 ng/ml (p = 0.001, Mann-Whitney U-test), and MMP-9, median 76 versus 40 ng/ml (p = 0.011, Mann-Whitney U-test).
Discussion
In this study, we find that patients with neovascular AMD have a significantly lower plasma concentration of TIMP-3. Also, we find an increase in TIMP-1 levels in patients with GA. We are unable to find any previous studies quantifying plasma TIMP in the different late stages of AMD, and therefore, we provide novel information on the association of lower TIMP-3 levels to the presence of CNV and higher TIMP-1 levels to the presence of GA.
Previous studies in AMD come to divergent conclusions on systemic levels of MMPs and TIMPs. Chau et al. (2008) assessed plasma levels of MMP-2 and MMP-9 in patients with AMD and found that MMP-9 was increased in both early and neovascular AMD when compared to healthy controls. A later study by Zeng et al. (2013) was not able to reproduce these findings and found no differences in serum levels of MMP-2, MMP-9, TIMP-1 or TIMP-3 between patients with early or neovascular AMD and healthy controls. Sharma et al. (2017) found increased TIMP-3 levels in serum of patients with early and late AMD. When interpreting and comparing the results of different studies, it is important to acknowledge differences in sample collection and analytical methods. First, serum is the extracellular portion of the blood after completion of coagulation, whereas plasma tubes contain anticoagulants that allow sampling of the extracellular portion of the blood without occurrence of coagulation. Blood leucocytes and platelets have abundant levels of MMPs and TIMPs (Santos-Martinez et al. 2008) , which are released in the samples after venepuncture (Jonsson et al. 2016) . Second, different immunoassays, with differences in reference as well as antibody affinity and avidity, lead to results that vary between the studies and complicate a direct comparison.
We find that TIMP-3 was present at a much lower systemic concentration than any of the other proteins measured. This was expected, as TIMP-3 is less soluble, and tightly sequestered in the ECM (Leco et al. 1994; Lee et al. 2007 ). The change in TIMP-3 in neovascular AMD is interesting, as genomewide association studies have reported that rs9621532 near the TIMP-3 region is associated with the risk of neovascular AMD, but not GA (Ardeljan et al. 2013) . As MMP-2 and MMP-9 are overexpressed in CNV and accelerate growth of CNV, it has been suspected that such an imbalance of homeostasis in ECM is part of CNV formation (Nagy et al. 2008) . These hypotheses are supported by studies identifying TIMP-1 and TIMP-3 in proximity of subfoveal fibrovascular membranes (Steen et al. 1998; Jonas et al. 2012) . In our study, we find the TIMP-3/MMP-2 ratio is significantly lower in patients with neovascular AMD, supporting the theory that an imbalance in the ratio TIMP-3/MMPs allows degradation and neovascularization.
The aged BrM is characterized by increased thickness. This age-related thickness is associated with increased risk of disease (Spraul et al. 1996 (Spraul et al. , 1999 and caused by increased deposition of lipid-containing debris as well as crosslinked collagen fibres and oxidized waste products of RPE metabolism, all suggesting a change in ECM regulation (Ramratten et al. 1994) . Consequently, the elasticity and hydraulic permeability of the BrM is subject to change (Starita et al. 1996) , which presumably leads to poorer blood-retinal barrier as well as loss of clearance function. In addition, Fernandez-Godino et al. (2018) have found that RPE cells grown on abnormal BrM explants from donors with AMD show a chronic activation of the alternative pathway of the complement system by excessive deposition of C3b.
Tissue inhibitor of metalloproteinase (TIMP)-3 has a direct anti-angiogenic effect as TIMP-3 binds competitively to vascular endothelial growth factor (VEGF) receptor-2 and therefore blocks the effect of VEGF (Qi et al. 2003 (Qi et al. , 2013 . This effect mechanism is in line with the present findings, if the systemic levels reflect the available TIMP-3 in the retina. The clinical relevance of TIMP-3 dysfunction is exemplified in patients with Sorsby's fundus dystrophy (SFD). Sorsby's fundus dystrophy (SFD) is a rare autosomal dominant disease, where a mutation in the TIMP-3 gene gives rise to macular dystrophy, causing drusenlike deposits and progresses to late stages. Late-stage SFD is primarily seen with CNV. Ultimately, SFD leads to loss of central visual function. The only treatment available is anti-VEGF injections in cases of CNV, which postpones vision loss. Sorsby's fundus dystrophy (SFD) has typically onset around the age of 40, and although SFD is a monogenic disease, it has striking similarities to AMD (Hamilton et al. 1989; Gourier & Chong 2015) . Patients with SFD show no increase in gene expression of mutated TIMP-3, but still accumulate mutated TIMP-3 in BrM at disease onset (Chong et al. 2003) . A similar accumulation of TIMP-3 is seen in BrM in increasing age and especially in cases of AMD. It has been suggested that the increased concentration is due to accumulation, as TIMP-3 mRNA remains unchanged in increasing age (Guo et al. 1999; Bailey et al. 2001) . It is possible that an increased adherence to ECM leads to a loss of free TIMP-3. This might orchestrate a lower capacity in inhibition of angiogenesis, further leading to CNV formation (Qi et al. 2009 ).
In this study, patients with GA had a higher concentration of TIMP-1 and MMP-9. Tissue inhibitor of metalloproteinase (TIMP)-1 is also described as being anti-angiogenic, besides its inhibitory effect towards MMPs (Bloomston et al. 2002; Akahane et al. 2004) . A study has found that the microRNA- processing enzyme DICER1 is critical in growth of new capillary vessels and that deficiency of DICER1 is associated with increased TIMP-1 expression in ovarian cells (Otsuka et al. 2008) . This is interesting, as expression of DICER1 is lower in RPE cells from human donors with GA (Kaneko et al. 2011) . The role of TIMP-1 in GA needs to be further explored, but DICER1 deficiency in RPE and endothelial cells could provide explanation for the increase in soluble TIMP-1 in patients with GA. We also found a positive correlation between age and TIMP-1 in patients with GA. This correlation was not present in either healthy controls or patients with neovascular AMD. This has not been reported before and the underlying mechanism needs to be investigated, but it seems that the cause of increased TIMP-1 is increasing over time in patients with GA. The dysregulation of TIMP-1 and MMP-9 is a characteristic that the patients with GA share with other neurodegenerative diseases (Lorenzl et al. 2003a,b) . Interestingly, TIMP-1 and MMP-9 are increased in expression around depositions of bamyloid in post-mortem brains with Alzheimer's disease (Peress et al. 1995; Asahina et al. 2001 ).
Study limitations should be noted when interpreting the results. This study is observational, and therefore, we can only speculate on causality. It is also important to note that MMP-9 levels are related to pro-MMP-9 levels which in turn are determined by polymorphisms in the sequence of cytosineadenine repeats in the promoter region of the MMP-9 gene (Shimajiri et al. 1999) . Alleles with a higher number of repeats increase levels of MMP-9 in mice (Fornoni et al. 2002) , and patients with AMD more frequently possess 22 or more of such repeat sequences (Fiotti et al. 2005) . Studies combining systemic levels with genetic analyses may give more detailed insight into MMP-9-related mechanisms.
Also, this study does not describe the expression or the activity of the enzymatic proteins measured. Therefore, we are unable to tell whether the altered systemic concentration is due to a lower expression or a lower turnover, that is due to accumulation in the ECM. All participants with neovascular AMD received treatment with anti-VEGF, and we were not able to include untreated patients due to ethical considerations. This means that we were unable to eliminate the risk of a potential systemic influence of anti-VEGF on MMP and TIMP levels. We avoided inclusion within 6 or 8 weeks from the treatment to consider this possible effect.
In conclusion, we find that TIMP-3 levels in patients with neovascular AMD differ significantly from patients with geographic atrophy and healthy controls. Patients with GA have significantly increased levels of plasma TIMP-1 and MMP-9. Changes in ECM regulation are a key feature in BrM in AMD. Tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-3 have specific regulatory properties in angiogenesis. Tissue inhibitor of metalloproteinase (TIMP)-1 has not previously been described in geographic atrophy, and its role needs to be elucidated. This study supports the theory that TIMP dysregulation has a role in AMD and sheds light on the possible susceptibility to choroidal neovascularization or atrophy of the neuroretina.
